Oragenics, Inc., a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, announced that it intends to offer to sell shares of its common stock in lieu thereof) in an underwritten public offering.
February 27, 2024
· 5 min read